EMERYVILLE, Calif., Feb. 25,
2025 /PRNewswire/ -- Dynavax Technologies
Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical
company developing and commercializing innovative vaccines,
today announced that the Company will participate in the following
upcoming investor conferences:
- TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 1:10
p.m. ET
- Barclays 27th Annual Global Healthcare Conference on
Tuesday, March 11 at 10:00 a.m. ET
The presentations will be webcast and may be accessed through
the "Events & Presentations" page on the "Investors" section of
the Company's website at
https://investors.dynavax.com/events-presentations.
About Dynavax
Dynavax is a commercial-stage
biopharmaceutical company developing and commercializing innovative
vaccines to help protect the world against infectious diseases. The
Company has two commercial products, HEPLISAV-B® vaccine
[Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved
in the U.S., the European Union and the United Kingdom for the prevention of infection
caused by all known subtypes of hepatitis B virus in adults 18
years of age and older, and CpG 1018® adjuvant,
currently used in HEPLISAV-B and multiple adjuvanted COVID-19
vaccines. For more information about our marketed products and
development pipeline, visit www.dynavax.com.
For Investors/Media:
Paul
Cox
pcox@dynavax.com
510-665-0499
Nicole Arndt
narndt@dynavax.com
510-665-7264
View original content to download
multimedia:https://www.prnewswire.com/news-releases/dynavax-to-participate-in-upcoming-investor-conferences-302385222.html
SOURCE Dynavax Technologies
